SAB Biotherapeutics’ (SABS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research note published on Wednesday morning,Benzinga reports. The firm currently has a $6.00 price target on the stock.

SABS has been the subject of a number of other reports. Chardan Capital reissued a “buy” rating and set a $25.00 price objective on shares of SAB Biotherapeutics in a report on Thursday, November 7th. Craig Hallum assumed coverage on shares of SAB Biotherapeutics in a report on Wednesday, October 9th. They set a “buy” rating and a $11.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, SAB Biotherapeutics presently has a consensus rating of “Buy” and an average target price of $12.40.

SAB Biotherapeutics Trading Up 7.7 %

NASDAQ SABS opened at $2.23 on Wednesday. SAB Biotherapeutics has a twelve month low of $2.01 and a twelve month high of $6.30. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.69 and a quick ratio of 3.69. The company’s 50-day simple moving average is $3.63 and its 200 day simple moving average is $3.13.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. As a group, analysts predict that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SAB Biotherapeutics

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. Kovitz Investment Group Partners LLC acquired a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the third quarter, according to its most recent filing with the SEC. The firm acquired 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned about 0.21% of SAB Biotherapeutics as of its most recent filing with the SEC. 7.82% of the stock is owned by institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.